Phase 1 Long COVID Trial, Recruiting NCT06920628 Sponsor: National Institute of Mental Health (NIMH) Condition: Long COVID
Back to Long Covid

Phase 1 Long COVID Trial, Recruiting

NCT06920628
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with neurological Long COVID (Neuro-PASC):

  • People between 18 and 70 years old
  • People who are in generally good health, based on their medical history and a physical check-up
  • People who are able to understand what the study involves and sign a consent form agreeing to participate
  • People who have already been assessed under specific NIH research programs (protocol #000089 or #000711) and have been found to have neurological Long COVID (Neuro-PASC)
  • People who have had the blood flow in their wrist checked to confirm it is adequate, and who have no metal or foreign objects in either wrist
  • People who agree to follow the lifestyle guidelines set out by the study

For healthy volunteers:

  • People between 18 and 70 years old
  • People who are able to give informed consent
  • People who are in generally good health with no cognitive (thinking or memory) difficulties
  • People who do not currently have an active COVID-19 infection
  • People who are at least six weeks past the start of any COVID-19 symptoms and have been fever-free for at least one week
  • People who report having had at least one COVID-19 infection in the past
  • People who are already enrolled in one of two specific NIH research programs (01M0254 or 17M0181)
  • People who have had the blood flow in their wrist checked to confirm it is adequate, and who have no metal or foreign objects in either wrist
  • People who agree to follow the lifestyle guidelines set out by the study

Who may not be able to join:

For people with neurological Long COVID (Neuro-PASC):

  • People with significant abnormalities on a heart trace (EKG) or blood tests, including certain kidney, blood sugar, or other chemical levels outside acceptable ranges (confirm with trial site)
  • People who have taken anti-inflammatory pain medicines (such as ibuprofen or aspirin-type drugs known as NSAIDs) within two weeks before a PET scan, or who have taken steroid tablets or immune-suppressing medicines within one month before a PET scan (topical/skin steroids are an exception)
  • People with a diagnosed substance use disorder or alcohol use disorder — note that casual use of alcohol or cannabis alone is not an automatic reason for exclusion, unless it affects daily functioning
  • People with an unstable medical condition that the research team considers makes participation unsafe, such as an active infection or untreated cancer
  • People who are unable to travel to the NIH
  • People who have recently taken part in other research involving radiation (such as other PET scans), where the combined radiation exposure would exceed the permitted safety limit
  • People who are unable to lie flat and still for at least two hours, including those with claustrophobia, those whose weight exceeds the scanner's maximum limit, or those with uncontrollable movement or behavioural symptoms
  • People who cannot safely have an MRI scan due to certain metal devices or implants in the body, such as pacemakers, brain stimulators, aneurysm clips, metal prosthetics, cochlear implants, permanent eyeliner, implanted pumps, or metal fragments in the eye
  • People who are pregnant or breastfeeding
  • People living with HIV

For healthy volunteers:

  • People with significant abnormalities on a heart trace (EKG) or blood tests, including kidney, blood sugar, or other chemical levels outside acceptable ranges (confirm with trial site)
  • People who have taken NSAID pain medicines within two weeks before the PET scan, or steroid tablets or immune-suppressing medicines within one month before the PET scan (topical/skin steroids are an exception)
  • People who currently have an active COVID-19 infection
  • People with a diagnosed substance use disorder or alcohol use disorder — casual use of alcohol or cannabis alone is not an automatic reason for exclusion, unless it affects daily functioning
  • People who are unable to travel to the NIH
  • People who have recently taken part in other research involving radiation where the combined exposure would exceed the permitted safety limit
  • People who are unable to lie flat and still for at least two hours, including those with claustrophobia, those whose weight exceeds the scanner's maximum limit, or those with uncontrollable movement or behavioural symptoms
  • People who cannot safely have an MRI scan due to certain metal devices or implants in the body, such as pacemakers, brain stimulators, aneurysm clips, metal prosthetics, cochlear implants, permanent eyeliner, implanted pumps, or metal fragments in the eye
  • People who are pregnant or breastfeeding
  • People living with HIV

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Robert B Innis, M.D., National Institute of Mental Health (NIMH)

Phone: (301) 827-6599

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
18 June 2025
Est. completion
22 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To measure distribution volume for 11C-PS13

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov